Workflow
Immunocore(IMCR)
icon
Search documents
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet
ZACKS· 2025-06-02 15:01
Group 1 - Immunocore Holdings PLC (IMCR) shares have increased by 20.2% over the past four weeks, closing at $36.60, with a mean price target of $60.47 indicating a potential upside of 65.2% [1] - The average of 15 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $21.18, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the expectation of an upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the past month, with seven estimates revised higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement, which appears to be a good guide [13]
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
Globenewswire· 2025-06-02 11:00
Core Insights - Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases [1][3] - The company will participate in the 2025 Jefferies Global Healthcare Conference, indicating its ongoing engagement with investors and the healthcare community [1][2] Company Overview - Immunocore is pioneering a novel class of TCR bispecific immunotherapies known as ImmTAX, aimed at treating a wide range of diseases [3] - The company has a robust pipeline with multiple active clinical and pre-clinical programs across oncology, infectious diseases, and autoimmune diseases [3] - KIMMTRAK, Immunocore's leading oncology TCR therapeutic, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several regions including the US, EU, Canada, Australia, and the UK [3]
Is it a Good Idea to Invest in Immunocore Stock Right Now?
ZACKS· 2025-05-23 14:31
Core Insights - Immunocore's Kimmtrak is experiencing significant sales growth, generating $310 million in 2024, a nearly 30% increase year-over-year, with Q1 2025 sales rising 33.6% to $93.9 million [2][5][8] Company Performance - Immunocore's stock has increased by 5.8% year-to-date, contrasting with a 5.5% decline in the industry [3] - The company has a Zacks Rank 1 (Strong Buy), with narrowed loss per share estimates for 2025 from $1.50 to $0.86 and for 2026 from $1.68 to $1.34 [9] Product Development - Kimmtrak is approved in 39 countries and launched in 26, serving as the standard of care for metastatic uveal melanoma in most markets [1][5] - Ongoing label expansion studies for Kimmtrak aim to target earlier-line settings for melanoma indications [5] - Immunocore is developing brenetafusp in combination with Bristol Myers' Opdivo for first-line advanced cutaneous melanoma, with additional studies across various tumor types [6] Market Context - Bristol Myers' Opdivo recorded $2.26 billion in sales in Q1 2025, highlighting its significance as a growth driver in oncology [7]
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
ZACKS· 2025-05-16 15:01
Group 1 - Immunocore Holdings PLC (IMCR) closed at $29.06, with a 2.3% gain over the past four weeks, and has a mean price target of $62.29, indicating an upside potential of 114.4% [1] - The average of 14 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $23.44, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the last 30 days, with seven estimates moving higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement [13]
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics
ZACKS· 2025-05-07 14:36
For the quarter ended March 2025, Immunocore Holdings PLC Sponsored ADR (IMCR) reported revenue of $93.88 million, up 33.2% over the same period last year. EPS came in at $0.10, compared to -$0.49 in the year-ago quarter.The reported revenue represents a surprise of +7.84% over the Zacks Consensus Estimate of $87.06 million. With the consensus EPS estimate being -$0.35, the EPS surprise was +128.57%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...
Immunocore(IMCR) - 2025 Q1 - Quarterly Results
2025-05-07 11:33
[Q1 2025 Report Overview](index=1&type=section&id=Immunocore%20reports%20first%20quarter%20financial%20results%20and%20provides%20a%20business%20update) The company reports strong Q1 2025 results driven by KIMMTRAK revenue growth and pipeline advancements - Immunocore reported strong Q1 2025 results, highlighted by significant year-over-year revenue growth for its lead product, KIMMTRAK, and progress across its oncology, infectious disease, and autoimmune pipelines[1](index=1&type=chunk)[2](index=2&type=chunk) **Q1 2025 Key Highlights** | Metric | Value | Note | | :--- | :--- | :--- | | KIMMTRAK Net Revenues | $93.9 million | +33% Year-over-Year | | Cash & Marketable Securities | $837 million | As of March 31, 2025 | | Net Income | $5.0 million | Compared to a net loss of $24.4 million in Q1 2024 | | Diluted EPS | $0.10 | Compared to $(0.49) in Q1 2024 | - Key clinical trial milestones are on track, including completing enrollment for the Phase 3 TEBE-AM trial in 1H 2026 and dose selection for the Phase 3 PRISM-MEL-301 trial in 2H 2025[1](index=1&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Results) The company achieved profitability with a $5.0 million net income, driven by a 33% rise in KIMMTRAK sales [Q1 2025 Financial Results](index=2&type=section&id=Q1%202025%20Financial%20Results) The company achieved profitability with a $5.0 million net income, reversing a prior-year loss of $24.4 million **Q1 2025 vs Q1 2024 Financial Summary (in millions)** | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Net Revenue | $93.9 | $70.5 | +33.2% | | R&D Expenses | $56.5 | $57.5 | -1.7% | | SG&A Expenses | $40.2 | $39.3 | +2.3% | | Net Income / (Loss) | $5.0 | $(24.4) | N/A | | Diluted EPS | $0.10 | $(0.49) | N/A | | Cash & Marketable Securities | $837.0 | - | - | **KIMMTRAK Q1 2025 Net Sales by Region (in millions)** | Region | Net Sales | | :--- | :--- | | United States | $56.6 | | Europe | $32.8 | | International | $4.5 | | **Total** | **$93.9** | - Growth in Europe was driven by increased demand, new country launches, and a **one-time favorable revenue adjustment of $6.0 million** from price negotiations in France and Germany[10](index=10&type=chunk)[26](index=26&type=chunk) [Business and Pipeline Update](index=2&type=section&id=Business%20and%20Pipeline%20Update) Updates highlight KIMMTRAK's commercial success and progress across the oncology, infectious disease, and autoimmune pipelines [KIMMTRAK® (tebentafusp)](index=2&type=section&id=KIMMTRAK) KIMMTRAK maintains its standard-of-care status for mUM with strong sales and ongoing label expansion trials - KIMMTRAK is now **approved in 39 countries** and launched in 26 for HLA-A*02:01 positive people with metastatic uveal melanoma (mUM)[7](index=7&type=chunk)[10](index=10&type=chunk) - Key growth areas include continued global expansion in mUM, and potential expansions into **2L+ advanced cutaneous melanoma (CM)** and adjuvant uveal melanoma[8](index=8&type=chunk) - The registrational Phase 3 TEBE-AM trial for 2L+ advanced CM is enrolling and expects to **complete enrollment in the first half of 2026**[9](index=9&type=chunk)[14](index=14&type=chunk) - The EORTC is enrolling patients in the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM), targeting a high-risk patient population of up to 1,200[14](index=14&type=chunk)[37](index=37&type=chunk) [Oncology Pipeline](index=3&type=section&id=PRAME%20portfolio) The PRAME franchise leads the oncology pipeline, with brenetafusp advancing in a Phase 3 trial for melanoma - The Phase 3 PRISM-MEL-301 trial is evaluating brenetafusp + nivolumab in 1L advanced cutaneous melanoma, with the company on track to **select the go-forward dose in 2H 2025**[11](index=11&type=chunk)[15](index=15&type=chunk)[33](index=33&type=chunk) - Brenetafusp is also being evaluated in a Phase 1/2 trial in multiple solid tumors, including ovarian and non-small cell lung cancer (NSCLC), in combination with various standard-of-care therapies[11](index=11&type=chunk)[13](index=13&type=chunk) - IMC-P115C, a half-life extended version of brenetafusp designed for less frequent dosing, is enrolling in a Phase 1 dose escalation trial[17](index=17&type=chunk)[18](index=18&type=chunk) - A Phase 1/2 trial is enrolling for IMC-R117C, which targets PIWIL1, for patients with advanced solid tumors including colorectal cancer[18](index=18&type=chunk) [Infectious Disease Pipeline (ImmTAV)](index=4&type=section&id=ImmTAV%20candidates%20for%20a%20functional%20cure%20in%20infectious%20diseases) The ImmTAV platform shows promise for functional cures in HIV and HBV, with positive initial data for its HIV candidate - At CROI 2025, initial data for HIV candidate IMC-M113V showed it was **well-tolerated with no serious adverse events**, and dose escalation is ongoing[1](index=1&type=chunk)[19](index=19&type=chunk) - In the HIV trial, **3 out of 10 evaluable patients at higher doses showed delayed viral rebound** or viremia control during treatment interruption[19](index=19&type=chunk)[24](index=24&type=chunk) - For the HBV candidate, IMC-I109V, the company plans to report data from the single ascending dose portion of its Phase 1 trial in the **second half of 2025**[20](index=20&type=chunk) [Autoimmune Disease Pipeline (ImmTAAI)](index=5&type=section&id=Tissue-specific%20down%20modulation%20of%20the%20immune%20system%20for%20autoimmune%20diseases) The ImmTAAI platform is advancing candidates for type 1 diabetes and atopic dermatitis using tissue-specific immune suppression - The company is on track to file a CTA or IND for **IMC-S118AI (for type 1 diabetes) in the second half of 2025**[25](index=25&type=chunk) - A CTA/IND filing is planned for **2026 for IMC-U120AI**, a universal (non-HLA-restricted) candidate for atopic dermatitis[25](index=25&type=chunk) - The ImmTAAI platform's key differentiator is its ability to suppress pathogenic T cells via PD1 agonism only when tethered to the target tissue, aiming for **localized immune modulation**[21](index=21&type=chunk) [About Immunocore & Technology Platforms](index=6&type=section&id=About%20Immunocore%20%26%20Technology%20Platforms) The company leverages three proprietary TCR technology platforms for cancer, infectious diseases, and autoimmune disorders [Technology Platforms](index=6&type=section&id=Technology%20Platforms) The company's core technologies include ImmTAC®, ImmTAV, and ImmTAAI for distinct therapeutic areas - **ImmTAC® (for Cancer):** Soluble TCRs designed to recognize intracellular cancer antigens and kill cancer cells via an anti-CD3 effector function[28](index=28&type=chunk) - **ImmTAV (for Infectious Diseases):** Novel bispecifics designed to enable the immune system to recognize and eliminate virally infected cells, aiming for functional cures in diseases like HIV and HBV[30](index=30&type=chunk)[31](index=31&type=chunk) - **ImmTAAI (for Autoimmune Diseases):** Novel bispecifics designed for tissue-specific down-modulation of the immune system by suppressing pathogenic T cells via PD1 receptor agonism[32](index=32&type=chunk) [KIMMTRAK® Safety Information](index=9&type=section&id=IMPORTANT%20SAFETY%20INFORMATION) KIMMTRAK carries a boxed warning for Cytokine Release Syndrome and other significant risks like skin reactions - **Boxed Warning - Cytokine Release Syndrome (CRS):** CRS occurred in **89% of patients** (0.8% grade 3/4) and requires monitoring for at least 16 hours after the first three infusions[42](index=42&type=chunk) - **Skin Reactions:** Occurred in **91% of patients**, including rash, pruritus, and cutaneous edema, which may require management with antihistamines or steroids[43](index=43&type=chunk) - **Elevated Liver Enzymes:** Occurred in **65% of patients**, requiring liver function monitoring before and during treatment[44](index=44&type=chunk) - **Embryo-Fetal Toxicity:** KIMMTRAK may cause fetal harm, and patients of reproductive potential should use effective contraception[46](index=46&type=chunk) [Financial Statements](index=13&type=section&id=Financial%20Statements) This section presents the condensed consolidated statements of operations, balance sheets, and cash flows for Q1 2025 [Condensed Consolidated Statement of Operations](index=13&type=section&id=Condensed%20Consolidated%20Statement%20of%20Operations) The company reported total revenues of $93.9 million and a net income of $5.0 million for the quarter **Condensed Consolidated Statement of Operations (In thousands, except per share data)** | | Quarter Ended March 31, 2025 | Quarter Ended March 31, 2024 | | :--- | :--- | :--- | | **Total revenue** | **$93,881** | **$70,502** | | Loss from operations | $(3,616) | $(26,490) | | **Net income (loss)** | **$5,023** | **$(24,436)** | | Basic net income (loss) per share | $0.10 | $(0.49) | | Diluted net income (loss) per share | $0.10 | $(0.49) | [Condensed Consolidated Balance Sheets](index=14&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The company maintained a strong financial position with $837.0 million in cash and marketable securities **Condensed Consolidated Balance Sheets (In thousands)** | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $476,845 | $455,731 | | Marketable securities | $360,185 | $364,645 | | **Total current assets** | **$948,625** | **$929,864** | | **Total assets** | **$1,028,008** | **$1,009,506** | | Total current liabilities | $149,163 | $212,181 | | **Total liabilities** | **$649,529** | **$648,790** | | **Total shareholders' equity** | **$378,479** | **$360,716** | [Summary Condensed Consolidated Statements of Cash Flows](index=15&type=section&id=Summary%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operating activities was positive at $0.4 million, a significant improvement from the prior year **Summary Condensed Consolidated Statements of Cash Flows (In thousands)** | | Quarter Ended March 31, 2025 | Quarter Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $435 | $(4,587) | | Net cash provided by (used in) investing activities | $9,702 | $(430) | | Net cash provided by financing activities | $2,551 | $396,012 | | **Cash and cash equivalents at end of period** | **$476,845** | **$832,821** | [Forward-Looking Statements](index=11&type=section&id=Forward%20Looking%20Statements) This section outlines the risks and uncertainties associated with the company's forward-looking statements [Forward-Looking Statements Disclaimer](index=11&type=section&id=Forward%20Looking%20Statements%20Disclaimer) The report's forward-looking statements are subject to numerous risks and uncertainties that could affect actual results - The report contains forward-looking statements concerning the company's clinical pipeline, commercial performance of KIMMTRAK, trial enrollment and results, and potential regulatory approvals[52](index=52&type=chunk) - These statements are subject to significant risks and uncertainties, including macroeconomic impacts, supply chain issues, regulatory hurdles, clinical trial delays or failures, and competition, as detailed in the company's SEC filings[52](index=52&type=chunk)
Immunocore(IMCR) - 2025 Q1 - Quarterly Report
2025-05-07 11:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | England and Wales | Not A ...
Immunocore reports first quarter financial results and provides a business update
Globenewswire· 2025-05-07 11:00
Core Insights - Immunocore reported a strong revenue performance in Q1 2025, with net revenues of $93.9 million, reflecting a 33% year-over-year growth, primarily driven by the sales of KIMMTRAK [1][2][3] Financial Results - Total net product revenue from KIMMTRAK was $93.9 million in Q1 2025, an increase from $70.3 million in Q1 2024, with $56.6 million generated in the United States, $32.8 million in Europe, and $4.5 million in international regions [3][24] - Research and development expenses for Q1 2025 were $56.5 million, slightly down from $57.5 million in Q1 2024, while selling, general, and administrative expenses increased to $40.2 million from $39.3 million [4][25] - The company achieved a net income of $5.0 million in Q1 2025, compared to a net loss of $24.4 million in the same period in 2024, with basic and diluted income per share at $0.10, up from a loss of $(0.49) [5][20] Product and Market Updates - KIMMTRAK is approved in 39 countries and launched in 26 countries for HLA-A*02:01 positive patients with metastatic uveal melanoma, continuing to be the standard of care in most markets [6][36] - The company is focusing on three key growth areas for KIMMTRAK: global expansion in metastatic uveal melanoma, potential expansion into second-line advanced cutaneous melanoma, and adjuvant uveal melanoma [7] - KIMMTRAK net product sales in the U.S. grew by 13% year-over-year, with increased demand driven by community outreach and new country launches in Europe and international regions [8] Research and Development Progress - Immunocore is on track for the Phase 3 TEBE-AM trial to complete enrollment in the first half of 2026 and for dose selection in the Phase 3 PRISM-MEL-301 trial in the second half of 2025 [1][14] - Initial multiple ascending dose data for the HIV functional cure candidate was presented at CROI 2025, with ongoing dose escalation [1][22] - The company is advancing its PRAME portfolio, with brenetafusp being evaluated in combination with nivolumab in a Phase 3 trial for first-line advanced cutaneous melanoma [10][15]
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet
ZACKS· 2025-04-30 15:00
Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 6.4% over the past four weeks to close the last trading session at $30.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $63.21 indicates a potential upside of 107.5%.The average comprises 14 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $23.20. While the low ...
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?
ZACKS· 2025-03-21 15:25
Immunocore Holdings PLC Sponsored ADR (IMCR) shares ended the last trading session 6% higher at $30.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.6% loss over the past four weeks.Earlier this month, the company presented encouraging initial data from the multiple ascending dose portion of the phase I/II STRIVE study evaluating its functional cure candidate, IMC-M113V, for treating human immunodeficiency vir ...